<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33414419</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2041-4889</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jan</Month>
              <Day>06</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cell death &amp; disease</Title>
          <ISOAbbreviation>Cell Death Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Gefitinib initiates sterile inflammation by promoting IL-1β and HMGB1 release via two distinct mechanisms.</ArticleTitle>
        <Pagination>
          <StartPage>49</StartPage>
          <MedlinePgn>49</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">49</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41419-020-03335-7</ELocationID>
        <Abstract>
          <AbstractText>Anticancer drug gefitinib causes inflammation-based side effects, such as interstitial pneumonitis. However, its mechanisms remain unknown. Here, we provide evidence that gefitinib elicits pro-inflammatory responses by promoting mature-interleukin-1β (IL-1β) and high-mobility group box 1 (HMGB1) release. Mitochondrial reactive oxygen species (mtROS) driven by gefitinib stimulated the formation of the NLRP3 (NACHT, LRR and PYD-containing protein 3) inflammasome, leading to mature-IL-1β release. Notably, gefitinib also stimulated HMGB1 release, which is, however, not mediated by the NLRP3 inflammasome. On the other hand, gefitinib-driven mtROS promoted the accumulation of γH2AX, a hallmark of DNA damage, leading to the activation of poly (ADP-ribose) polymerase-1 (PARP-1) and subsequent active release of HMGB1. Together our results reveal the potential ability of gefitinib to initiate sterile inflammation via two distinct mechanisms, and identified IL-1β and HMGB1 as key determinants of gefitinib-induced inflammation that may provide insights into gefitinib-induced interstitial pneumonitis.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Noguchi</LastName>
            <ForeName>Takuya</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0001-6187-6645</Identifier>
            <AffiliationInfo>
              <Affiliation>Laboratory of Health Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sekiguchi</LastName>
            <ForeName>Yuto</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Health Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kudoh</LastName>
            <ForeName>Yuki</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Health Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Naganuma</LastName>
            <ForeName>Rio</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Health Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kagi</LastName>
            <ForeName>Tomohiro</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Health Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nishidate</LastName>
            <ForeName>Akiko</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Health Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maeda</LastName>
            <ForeName>Kazuhiro</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Health Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ishii</LastName>
            <ForeName>Chizuru</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Health Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Toyama</LastName>
            <ForeName>Takashi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Molecular and Biochemical Toxicology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hirata</LastName>
            <ForeName>Yusuke</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-1428-2075</Identifier>
            <AffiliationInfo>
              <Affiliation>Laboratory of Health Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hwang</LastName>
            <ForeName>Gi-Wook</ForeName>
            <Initials>GW</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Molecular and Biochemical Toxicology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Laboratory of Environmental and Health Sciences, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University, Sendai, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Matsuzawa</LastName>
            <ForeName>Atsushi</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Health Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan. atsushi.matsuzawa.c6@tohoku.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>01</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cell Death Dis</MedlineTA>
        <NlmUniqueID>101524092</NlmUniqueID>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D024243">HMGB1 Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S65743JHBS</RegistryNumber>
          <NameOfSubstance UI="D000077156">Gefitinib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000077156" MajorTopicYN="N">Gefitinib</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024243" MajorTopicYN="N">HMGB1 Protein</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053583" MajorTopicYN="N">Interleukin-1beta</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>5</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33414419</ArticleId>
        <ArticleId IdType="pmc">PMC7791030</ArticleId>
        <ArticleId IdType="doi">10.1038/s41419-020-03335-7</ArticleId>
        <ArticleId IdType="pii">10.1038/s41419-020-03335-7</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat. Rev. Immunol. 2016;16:407–420. doi: 10.1038/nri.2016.58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri.2016.58</ArticleId>
            <ArticleId IdType="pubmed">27291964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rathinam VA, Fitzgerald KA. Inflammasome complexes: emerging mechanisms and effector functions. Cell. 2016;165:792–800. doi: 10.1016/j.cell.2016.03.046.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2016.03.046</ArticleId>
            <ArticleId IdType="pmc">PMC5503689</ArticleId>
            <ArticleId IdType="pubmed">27153493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marzano AV, et al.  Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet’s syndrome: a comprehensive review and disease classification criteria. Clin. Rev. Allergy Immunol. 2013;45:202–210. doi: 10.1007/s12016-012-8351-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12016-012-8351-x</ArticleId>
            <ArticleId IdType="pubmed">23334898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Q, Zhang D, Hu D, Zhou X, Zhou Y. The role of mitochondria in NLRP3 inflammasome activation. Mol. Immunol. 2018;103:115–124. doi: 10.1016/j.molimm.2018.09.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molimm.2018.09.010</ArticleId>
            <ArticleId IdType="pubmed">30248487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinvalet D. The role of the mitochondria and the endoplasmic reticulum contact sites in the development of the immune responses. Cell Death Dis. 2018;9:336. doi: 10.1038/s41419-017-0237-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-017-0237-7</ArticleId>
            <ArticleId IdType="pmc">PMC5832423</ArticleId>
            <ArticleId IdType="pubmed">29491398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sadatomi D, et al.  Mitochondrial function is required for extracellular ATP-induced NLRP3 inflammasome activation. J. Biochem. 2017;161:503–512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28096454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Y, Wang H, Kouadir M, Song H, Shi F. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis. 2019;10:128. doi: 10.1038/s41419-019-1413-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-019-1413-8</ArticleId>
            <ArticleId IdType="pmc">PMC6372664</ArticleId>
            <ArticleId IdType="pubmed">30755589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murakami T, et al.  Critical role for calcium mobilization in activation of the NLRP3 inflammasome. Proc. Natl Acad. Sci. USA. 2012;109:11282–11287. doi: 10.1073/pnas.1117765109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1117765109</ArticleId>
            <ArticleId IdType="pmc">PMC3396518</ArticleId>
            <ArticleId IdType="pubmed">22733741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu B, Wang H, Andersson U, Tracey KJ. Regulation of HMGB1 release by inflammasomes. Protein Cell. 2013;4:163–167. doi: 10.1007/s13238-012-2118-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13238-012-2118-2</ArticleId>
            <ArticleId IdType="pmc">PMC4533838</ArticleId>
            <ArticleId IdType="pubmed">23483477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tian J, et al.  Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 2007;8:487–496. doi: 10.1038/ni1457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni1457</ArticleId>
            <ArticleId IdType="pubmed">17417641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ditsworth D, Zong W-X, Thompson CB. Activation of poly (ADP)-ribose polymerase (PARP-1) induces release of the pro-inflammatory mediator HMGB1 from the nucleus. J. Biol. Chem. 2007;282:17845–17854. doi: 10.1074/jbc.M701465200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M701465200</ArticleId>
            <ArticleId IdType="pmc">PMC3140953</ArticleId>
            <ArticleId IdType="pubmed">17430886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Z, et al.  PARP-1 mediates LPS-induced HMGB1 release by macrophages through regulation of HMGB1 acetylation. J. Immunol. 2014;193:6114–6123. doi: 10.4049/jimmunol.1400359.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1400359</ArticleId>
            <ArticleId IdType="pubmed">25392528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Lee TC, Guillemin B, Yu MC, Rom WN. Enhanced IL-1 beta and tumor necrosis factor-alpha release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J. Immunol. 1993;150:4188–4196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8473757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishii H, et al.  Increased levels of interleukin-18 in bronchoalveolar lavage fluid of patients with idiopathic nonspecific interstitial pneumonia. Respiration. 2005;72:39–45. doi: 10.1159/000083399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000083399</ArticleId>
            <ArticleId IdType="pubmed">15753633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoshino T, et al.  Role of proinflammatory cytokines IL-18 and IL-1beta in bleomycin-induced lung injury in humans and mice. Am. J. Respir. Cell Mol. Biol. 2009;41:661–670. doi: 10.1165/rcmb.2008-0182OC.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1165/rcmb.2008-0182OC</ArticleId>
            <ArticleId IdType="pubmed">19265174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kong H, et al.  Involvement of NLRP3 inflammasome in rituximab-induced interstitial lung disease: a case report. J. Clin. Pharm. Ther. 2014;39:691–694. doi: 10.1111/jcpt.12198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jcpt.12198</ArticleId>
            <ArticleId IdType="pubmed">25131433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeuchi K, Ito F. EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors. FEBS J. 2010;277:316–326. doi: 10.1111/j.1742-4658.2009.07450.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1742-4658.2009.07450.x</ArticleId>
            <ArticleId IdType="pubmed">19922467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer. 2006;6:714–727. doi: 10.1038/nrc1913.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc1913</ArticleId>
            <ArticleId IdType="pubmed">16929325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hojjat-Farsangi M. Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies. Int. J. Mol. Sci. 2014;15:13768–13801. doi: 10.3390/ijms150813768.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms150813768</ArticleId>
            <ArticleId IdType="pmc">PMC4159824</ArticleId>
            <ArticleId IdType="pubmed">25110867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitsudomi T, et al.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121–128. doi: 10.1016/S1470-2045(09)70364-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(09)70364-X</ArticleId>
            <ArticleId IdType="pubmed">20022809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maemondo M, et al.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 2010;362:2380–2388. doi: 10.1056/NEJMoa0909530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa0909530</ArticleId>
            <ArticleId IdType="pubmed">20573926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao HY, et al.  Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804) J. Thorac. Oncol. 2015;10:655–664. doi: 10.1097/JTO.0000000000000445.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/JTO.0000000000000445</ArticleId>
            <ArticleId IdType="pubmed">25546556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoue A, et al.  Severe acute interstitial pneumonia and gefitinib. Lancet. 2003;361:137–139. doi: 10.1016/S0140-6736(03)12190-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(03)12190-3</ArticleId>
            <ArticleId IdType="pubmed">12531582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sekiguchi Y, et al.  The anti-cancer drug gefitinib accelerates Fas-mediated apoptosis by enhancing caspase-8 activation in cancer cells. J. Toxicological Sci. 2019;44:435–440. doi: 10.2131/jts.44.435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2131/jts.44.435</ArticleId>
            <ArticleId IdType="pubmed">31168030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tigno-Aranjuez JT, Asara JM, Abbott DW. Inhibition of RIP2’s tyrosine kinase activity limits NOD2-driven cytokine responses. Genes Dev. 2010;24:2666–2677. doi: 10.1101/gad.1964410.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.1964410</ArticleId>
            <ArticleId IdType="pmc">PMC2994040</ArticleId>
            <ArticleId IdType="pubmed">21123652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyake K, et al.  Epidermal growth factor receptor-tyrosine kinase inhibitor (gefitinib) augments pneumonitis, but attenuates lung fibrosis in response to radiation injury in rats. J. Med. Investig.: JMI. 2012;59:174–185. doi: 10.2152/jmi.59.174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2152/jmi.59.174</ArticleId>
            <ArticleId IdType="pubmed">22450006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sahillioglu AC, Sumbul F, Ozoren N, Haliloglu T. Structural and dynamics aspects of ASC speck assembly. Structure. 2014;22:1722–1734. doi: 10.1016/j.str.2014.09.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.str.2014.09.011</ArticleId>
            <ArticleId IdType="pubmed">25458835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lugrin J, Martinon F. Detection of ASC oligomerization by western blotting. Bio Protoc. 2017;7:e2292. doi: 10.21769/BioProtoc.2292.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21769/BioProtoc.2292</ArticleId>
            <ArticleId IdType="pmc">PMC5660620</ArticleId>
            <ArticleId IdType="pubmed">29085861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petrilli V, et al.  Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ. 2007;14:1583–1589. doi: 10.1038/sj.cdd.4402195.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.cdd.4402195</ArticleId>
            <ArticleId IdType="pubmed">17599094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eisenbarth SC, Colegio OR, O’Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature. 2008;453:1122–1126. doi: 10.1038/nature06939.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature06939</ArticleId>
            <ArticleId IdType="pmc">PMC4804622</ArticleId>
            <ArticleId IdType="pubmed">18496530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noguchi T, et al.  Nuclear-accumulated SQSTM1/p62-based ALIS act as microdomains sensing cellular stresses and triggering oxidative stress-induced parthanatos. Cell Death Dis. 2018;9:1193. doi: 10.1038/s41419-018-1245-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-018-1245-y</ArticleId>
            <ArticleId IdType="pmc">PMC6294141</ArticleId>
            <ArticleId IdType="pubmed">30546061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gurung P, Lukens JR, Kanneganti TD. Mitochondria: diversity in the regulation of the NLRP3 inflammasome. Trends Mol. Med. 2015;21:193–201. doi: 10.1016/j.molmed.2014.11.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molmed.2014.11.008</ArticleId>
            <ArticleId IdType="pmc">PMC4352396</ArticleId>
            <ArticleId IdType="pubmed">25500014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okon IS, Coughlan KA, Zhang M, Wang Q, Zou MH. Gefitinib-mediated reactive oxygen specie (ROS) instigates mitochondrial dysfunction and drug resistance in lung cancer cells. J. Biol. Chem. 2015;290:9101–9110. doi: 10.1074/jbc.M114.631580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M114.631580</ArticleId>
            <ArticleId IdType="pmc">PMC4423695</ArticleId>
            <ArticleId IdType="pubmed">25681445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smiley ST, et al.  Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc. Natl Acad. Sci. USA. 1991;88:3671–3675. doi: 10.1073/pnas.88.9.3671.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.88.9.3671</ArticleId>
            <ArticleId IdType="pmc">PMC51514</ArticleId>
            <ArticleId IdType="pubmed">2023917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park S, et al.  Defective mitochondrial fission augments NLRP3 inflammasome activation. Sci. Rep. 2015;5:15489. doi: 10.1038/srep15489.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep15489</ArticleId>
            <ArticleId IdType="pmc">PMC4614538</ArticleId>
            <ArticleId IdType="pubmed">26489382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen J, Chen ZJ. PtdIns4P on dispersed trans-Golgi network mediates NLRP3 inflammasome activation. Nature. 2018;564:71–76. doi: 10.1038/s41586-018-0761-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-018-0761-3</ArticleId>
            <ArticleId IdType="pubmed">30487600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frank D, Vince JE. Pyroptosis versus necroptosis: similarities, differences, and crosstalk. Cell Death Differ. 2019;26:99–114. doi: 10.1038/s41418-018-0212-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-018-0212-6</ArticleId>
            <ArticleId IdType="pmc">PMC6294779</ArticleId>
            <ArticleId IdType="pubmed">30341423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi J, Gao W, Shao F. Pyroptosis: gasdermin-mediated programmed necrotic cell death. Trends Biochem. Sci. 2017;42:245–254. doi: 10.1016/j.tibs.2016.10.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tibs.2016.10.004</ArticleId>
            <ArticleId IdType="pubmed">27932073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ariyama H, et al.  Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells. J. Cell. Biochem. 2006;97:724–734. doi: 10.1002/jcb.20678.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcb.20678</ArticleId>
            <ArticleId IdType="pubmed">16229013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tracy S, et al.  Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res. 2004;64:7241–7244. doi: 10.1158/0008-5472.CAN-04-1905.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-04-1905</ArticleId>
            <ArticleId IdType="pubmed">15492241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vande Walle L, Kanneganti TD, Lamkanfi M. HMGB1 release by inflammasomes. Virulence. 2011;2:162–165. doi: 10.4161/viru.2.2.15480.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/viru.2.2.15480</ArticleId>
            <ArticleId IdType="pmc">PMC3265758</ArticleId>
            <ArticleId IdType="pubmed">21422809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia C, et al.  Endothelial cell pyroptosis plays an important role in Kawasaki disease via HMGB1/RAGE/cathespin B signaling pathway and NLRP3 inflammasome activation. Cell Death Dis. 2019;10:778. doi: 10.1038/s41419-019-2021-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-019-2021-3</ArticleId>
            <ArticleId IdType="pmc">PMC6791856</ArticleId>
            <ArticleId IdType="pubmed">31611559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimizu H, et al.  Association of serum high-mobility group box protein 1 level with outcomes of acute exacerbation of idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia. PLoS ONE. 2018;13:e0196558. doi: 10.1371/journal.pone.0196558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0196558</ArticleId>
            <ArticleId IdType="pmc">PMC5967827</ArticleId>
            <ArticleId IdType="pubmed">29795561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamada N, et al.  The role of high mobility group box1 in pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 2008;39:440–447. doi: 10.1165/rcmb.2007-0330OC.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1165/rcmb.2007-0330OC</ArticleId>
            <ArticleId IdType="pubmed">18441281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coll RC, et al.  A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 2015;21:248–255. doi: 10.1038/nm.3806.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.3806</ArticleId>
            <ArticleId IdType="pmc">PMC4392179</ArticleId>
            <ArticleId IdType="pubmed">25686105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol. Cell. Biol. 1999;19:5237–5246. doi: 10.1128/MCB.19.8.5237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.19.8.5237</ArticleId>
            <ArticleId IdType="pmc">PMC84367</ArticleId>
            <ArticleId IdType="pubmed">10409715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Luo W, Wang Y. PARP-1 and its associated nucleases in DNA damage response. DNA Repair. 2019;81:102651. doi: 10.1016/j.dnarep.2019.102651.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.dnarep.2019.102651</ArticleId>
            <ArticleId IdType="pmc">PMC6764844</ArticleId>
            <ArticleId IdType="pubmed">31302005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Darisipudi MN, Allam R, Rupanagudi KV, Anders HJ. Polyene macrolide antifungal drugs trigger interleukin-1β secretion by activating the NLRP3 inflammasome. PLoS ONE. 2011;6:e19588. doi: 10.1371/journal.pone.0019588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0019588</ArticleId>
            <ArticleId IdType="pmc">PMC3100296</ArticleId>
            <ArticleId IdType="pubmed">21625424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sauter KA, Wood LJ, Wong J, Iordanov M, Magun BE. Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome. Cancer Biol. Ther. 2011;11:1008–1016. doi: 10.4161/cbt.11.12.15540.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/cbt.11.12.15540</ArticleId>
            <ArticleId IdType="pmc">PMC3142364</ArticleId>
            <ArticleId IdType="pubmed">21464611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Groß CJ, et al.  K + Efflux-independent NLRP3 inflammasome activation by small molecules targeting mitochondria. Immunity. 2016;45:761–773. doi: 10.1016/j.immuni.2016.08.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2016.08.010</ArticleId>
            <ArticleId IdType="pubmed">27692612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henriksbo BD, Tamrakar AK, Phulka JS, Barra NG, Schertzer JD. Statins activate the NLRP3 inflammasome and impair insulin signaling via p38 and mTOR. Am. J. Physiol. Endocrinol. Metab. 2020;319:E110–E116. doi: 10.1152/ajpendo.00125.2020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpendo.00125.2020</ArticleId>
            <ArticleId IdType="pubmed">32421368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henriksbo BD, et al.  Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance. Diabetes. 2014;63:3742–3747. doi: 10.2337/db13-1398.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/db13-1398</ArticleId>
            <ArticleId IdType="pubmed">24917577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao YH, et al.  HMG-CoA reductase inhibitors activate caspase-1 in human monocytes depending on ATP release and P2X7 activation. J. Leukoc. Biol. 2013;93:289–299. doi: 10.1189/jlb.0812409.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1189/jlb.0812409</ArticleId>
            <ArticleId IdType="pubmed">23159926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brehmer D, et al.  Cellular targets of gefitinib. Cancer Res. 2005;65:379–382.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15695376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karaman MW, et al.  A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008;26:127–132. doi: 10.1038/nbt1358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nbt1358</ArticleId>
            <ArticleId IdType="pubmed">18183025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duggan BM, Cavallari JF, Foley KP, Barra NG, Schertzer JD. RIPK2 dictates insulin responses to tyrosine kinase inhibitors in obese male mice. Endocrinology. 2020;161:bqaa086. doi: 10.1210/endocr/bqaa086.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/endocr/bqaa086</ArticleId>
            <ArticleId IdType="pubmed">32473019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Dawson VL, Dawson TM. Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos. Exp. Neurol. 2009;218:193–202. doi: 10.1016/j.expneurol.2009.03.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.expneurol.2009.03.020</ArticleId>
            <ArticleId IdType="pmc">PMC2752872</ArticleId>
            <ArticleId IdType="pubmed">19332058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kudoh S, et al.  Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am. J. Respir Crit. Care Med. 2008;177:1348–1357. doi: 10.1164/rccm.200710-1501OC.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.200710-1501OC</ArticleId>
            <ArticleId IdType="pubmed">18337594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hotta K, et al.  Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. Cancer J. 2005;11:417–424. doi: 10.1097/00130404-200509000-00010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00130404-200509000-00010</ArticleId>
            <ArticleId IdType="pubmed">16259873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Yang H, Zhao M, He J. Successful treatment of gefitinib-induced acute interstitial pneumonitis with corticosteroid and non-invasive BIPAP-ventilation. J. Thorac. Dis. 2012;4:316–319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3378190</ArticleId>
            <ArticleId IdType="pubmed">22754672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou FQ, He DK, Shao YR, Shen J. [The effects of methylprednisolone on NLRP3 inflammasome in rats with acute lung injury Induced by Phosgene] Zhonghua Lao Dong Wei Sheng Zhi Ye Bing. Za Zhi. 2018;36:573–579.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30317804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang L, et al.  EGFR TKIs impair lysosome-dependent degradation of SQSTM1 to compromise the effectiveness in lung cancer. Signal Transduct. Target Ther. 2019;4:25. doi: 10.1038/s41392-019-0059-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41392-019-0059-4</ArticleId>
            <ArticleId IdType="pmc">PMC6799834</ArticleId>
            <ArticleId IdType="pubmed">31637005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McKillop D, et al.  Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol. Cancer Therap. 2005;4:641–649. doi: 10.1158/1535-7163.MCT-04-0329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-04-0329</ArticleId>
            <ArticleId IdType="pubmed">15827338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Araki T, et al.  Review of the treatment of non-small cell lung cancer with gefitinib. Clin. Med. Insights Oncol. 2012;6:407–421. doi: 10.4137/CMO.S7340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4137/CMO.S7340</ArticleId>
            <ArticleId IdType="pmc">PMC3520446</ArticleId>
            <ArticleId IdType="pubmed">23239933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maruyama R, et al.  Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2008;26:4244–4252. doi: 10.1200/JCO.2007.15.0185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2007.15.0185</ArticleId>
            <ArticleId IdType="pubmed">18779611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yokosawa T, et al.  Pro-caspase-3 protects cells from polymyxin B-induced cytotoxicity by preventing ROS accumulation. J. Antibiot. (Tokyo) 2019;72:848–852. doi: 10.1038/s41429-019-0216-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41429-019-0216-6</ArticleId>
            <ArticleId IdType="pubmed">31371783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsuchida M, et al.  Pro-apoptotic functions of TRAF2 in p53-mediated apoptosis induced by cisplatin. J. Toxicol. Sci. 2020;45:219–226. doi: 10.2131/jts.45.219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2131/jts.45.219</ArticleId>
            <ArticleId IdType="pubmed">32238696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noguchi T, et al.  Brefeldin A-inhibited guanine nucleotide-exchange factor 1 (BIG1) governs the recruitment of tumor necrosis factor receptor-associated factor 2 (TRAF2) to tumor necrosis factor receptor 1 (TNFR1) signaling complexes. Int J. Mol. Sci. 2016;17:1869. doi: 10.3390/ijms17111869.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms17111869</ArticleId>
            <ArticleId IdType="pmc">PMC5133869</ArticleId>
            <ArticleId IdType="pubmed">27834853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirata Y, et al.  TRIM48 promotes ASK1 activation and cell death through ubiquitination-dependent degradation of the ASK1-negative regulator PRMT1. Cell Rep. 2017;21:2447–2457. doi: 10.1016/j.celrep.2017.11.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2017.11.007</ArticleId>
            <ArticleId IdType="pubmed">29186683</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
